Brian Abrahams: Thanks. It’s Brian Abrahams from RBC here. So just maybe continuing on Huntington’s, can you maybe talk a little bit about the initial dynamics that you’re seeing and maybe expand on those in terms of, de novo patients versus switchers and segments where you’re seeing or expecting to see the most uptake there? And then, secondarily, on the use of capital, it sounds like your primary focus remains on INGREZZA commercial growth and investment and focusing on the internal pipeline. But maybe you can just give us an update on your latest thinking on any sort of external collaborations or other strategic opportunities outside of Neurocrine in the past. You’ve been — you’ve kind of talked about the optionality that your balance sheet might give you there. Curious for your latest views? Thanks.
Kevin Gorman: Hi, Brian. So when it comes to use of capital, I don’t think there’s been any dramatic changes in our strategy and it’s worked out quite well for us. We’re going to first and foremost is to invest in INGREZZA and continue to bring this patient — this drug to as many patients as possible, and that’s why you see this continued very good growth. Second, what we’re doing, as you can see and as we’ll be discussing at some length in our R&D Day is the investment in ourselves from a research standpoint. And that’s going to be our transition of a company into multiple therapeutic modalities in the areas that we concentrate on, which is neuroscience, neuropsychiatry, neuroendocrinology and at some point in the very near future, neuroimmunology.
And then, finally, focusing on the pipeline that we currently have here, we have a number of readouts this quarter and into next year. We’re going to continue to invest in those products. And probably — not probably, what we will be investing in is going to be the submission for crinecerfont next year, getting ready for what we believe is going to be an AdCom for the drug, since it’s the first therapy for these patients in 60 plus years. And then, ultimately, knock on wood, the launch. So there’s our priorities. There’s our use of capital.
Eric Benevich: And I can comment on the question around patient types in Huntington’s Chorea. So this is an opportunity that is primarily going to be driven through our neurology sales force. And they’re calling on the Centers of Excellence for Huntington’s Disease, movement specialists, as well as general neurologists that treat these patients. If you think about the dynamics that I described earlier, with only about 20% of the eligible patient population currently being treated with the VMAT2 inhibitor, about half the time they’re not getting treated with anything and about a third of the time, roughly, are getting treated with antipsychotics primarily for psych symptoms and secondarily to help potentially improve the movements.
So the feedback we’re getting so far is very positive. And as I mentioned earlier, it’s very early days yet. But if you think about the types of patients that would be getting started on INGREZZA here at the outset of our launch, obviously, de novo patients that are newly diagnosed with Chorea. Certainly patients that have, for various reasons in the past, declined treatment. And as I said, that’s really the majority of the addressable patient pool. And then there are some patients that have tried and for whatever reason, have responded well to tetrabenazine or deutetrabenazine. Either they didn’t tolerate them or they weren’t able to achieve an effective maintenance dose. So these are all patient types that would be considered candidates for treatment with INGREZZA.
The one group that we’re not pushing for really is patients that are currently doing well on treatment. So I think that there’s a lot of growth opportunity within this new indication and we’re excited to make a difference here in the coming months and years.
Brian Abrahams: Thanks. It’s really helpful. Congrats again on the quarter.
Operator: Our next question comes from Akash Tewari with Jefferies. Please go ahead.
Unidentified Analyst: Hi. This is Stevie [ph] on for Akash. Now that you have both data sets for crinecerfont, which population, pediatrics or adults, will be the larger sales opportunity and what should we be modeling for duration of response? Thank you.
Eiry Roberts: Let me start. So in terms of the programs reading out, we believe that the unmet need is significant in both pediatric and adult patients with crinecerfont. As Kevin alluded to, there has been no new medication — in terms of medication types that are non-steroid related for this patient population for the last 60 years, 70 years. And so we do believe based on the strength and quality of the data that was generated in this program, that there is an opportunity for crinecerfont if approved to fundamentally change the treatment paradigm for these patients. And so I think that we will be focused on reaching every patient that we can, both in the adult and the pediatric setting, and our educational processes and support of both the clinicians, patients and caregivers will actually fall in both of those areas.
Kevin Gorman: So given the safety profile that we saw, as well as the efficacy, this is something that we would expect to be chronic treatment that a patient would get on. We would expect them to see the intravenous control and the benefit and should be safe to have as chronic treatment, but data will show that out.
Eiry Roberts: And just to support that, we obviously have ongoing open label data that is generating additional safety information, several years’ worth of data now in many patients and I think the goal would be to allow the flexibility of using this medication in a chronic way if approved.
Unidentified Analyst: Thank you.
Operator: Question comes from Josh Schimmer with Cantor. Please go ahead.
Josh Schimmer: Thanks so much for taking the question and congrats on a very strong quarter. On the INGREZZA, I think in the past, even earlier this year, you indicated that the long-term care facility effort was still just getting off the ground. I think on this quarter, you indicated that there was good momentum in that segment. Can you talk a little bit about the dynamics there and what’s transpired over the course of the last year and whether that is starting to become a more meaningful contributor to revenue?
Kevin Gorman: Yeah. I do think it’s a meaningful contributor revenue and is certainly growing well, as I mentioned earlier. Certainly I think that going into this year, remember that we just launched our LTC sales force in the spring of 2022 and so we’re about a year and a half into this effort. And really the first few quarters were driving towards getting our targeting down, laying the foundation for TD in that space and you have to remember that this is essentially new in long-term care. And so our team has done a really nice job, I think, of educating the care teams in the long-term care facilities, understanding the dynamics with LTC pharmacies and have done a nice job of really driving diagnosis and now treatment within INGREZZA in the long-term care segment. So as I mentioned before, it’s growing nicely and its really part of the reason that we’ve had such a nice Q3.
